CCL23/MPIF-1 Antibody [Unconjugated]

Recombinant Human CCL23/MPIF‑1 (Catalog # 131‑M1) chemoattracts the BaF3 mouse pro‑B cell line transfected with human CCR1 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CCL23/MPIF‑1 (20 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human CCL23/MPIF‑1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF371). The ND50 is typically 0.5‑2.5 µg/mL.

• Reactivity: Hu
• Applications: WB, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

CCL23/MPIF-1 Antibody [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant human CCL23/MPIF-1
  Arg22-Asn120
  Accession # P55773
• Specificity: Detects human CCL23/MPIF‑1 in direct ELISAs and Western blots. In direct ELISAs, less than 10% cross-reactivity with recombinant human (rh) MIP-1δ, rhHCC-1, rhMIP-1 alpha and recombinant mouse MIP-1 gamma is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: CCL23
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 0.5-2.5 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CCL23/MPIF-1 Antibody [Unconjugated]

• CCL23
• CCL23/MPIF-1
• CCL23;CKb8;Ckb-8;Ckb-8-1;CK-BETA-8;hmrp-2a;MIP3;MIP-3;MPIF1;MPIF-1;SCYA23
• MPIF1
• MPIF-1

Background

Myeloid progenitor inhibitory factor (MPIF-1), also known as CK beta 8 and MIP-3, is a member of the CC chemokine subfamily that is designated CCL23. Alternative splicing of the MPIF-1 gene results in two mRNAs that encode a short (CK beta 8) and a long (CK beta 8-1) isoform of the chemokine. CK beta 8 cDNA encodes a 120 amino acid (aa) residue precursor protein with a putative 21 aa residue signal peptide that is cleaved to generate a 99 aa residue mature CK beta 8 (aa 22‑120). Additional N-terminal processing of the 99 aa residue variant can generate a 75 aa residue CK beta 8 (aa 46‑120) that is significantly more active than the 99 aa residue variant. Similarly, CK beta 8-1 encodes a 137 aa residue precursor protein that can give rise to a 116 and a 92 aa residue chemokine. Among CC chemokine members, MPIF-1 is most closely related to MIP-5/CCL15 (67% sequence identity) and MIP-1 alpha /CCL3 (51%). MPIF-1 mRNA is most abundant in the adult lung and liver, but is also present in bone marrow, placenta, and various myelomonocytic cell lines. MPIF-1 has been shown to suppress the low proliferative potential colony-forming cells that give rise to granulocyte and monocyte lineages. MPIF-1 binds to CCR1 with high affinity and has been shown to be a potent chemoattractant and activator of monocytes, dendritic cells, and osteoclast precursors.

1. Patel, V. et al. (1997) J. Exp. Med. 185:1163.
2. Youn, B-S. et al. (1998) Blood 91:3118.
3. Nardelli, B. et al. (1999) J. Leukoc. Biol. 61:822.
4. Berkhout, T.A. et al. (2000) Biochem. Pharmacol. 59:591.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: CCL23
• Uniprot:
  • P55773()